GSK plc

Aktuelle Version vom 14. September 2026, 17:22 Uhr

Out of the wikipedia:

GSK plc (an abbreviation of its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company.[3][4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham,[n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.

GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.[5]

The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange[6] behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK .[7]

The company developed the first malaria vaccine, RTS,S, which it said in 2014, it would make available for five per cent above cost.[8] Legacy products developed at GSK include several listed in the World Health Organization's List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine, and zidovudine.[9]

In 2012, under prosecution by the United States Department of Justice (DoJ) based on combined investigations of the Department of Health and Human Services (HHS-OIG), FDA and FBI, primarily concerning sales and marketing of the drugs Avandia, Paxil and Wellbutrin, GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data and kickbacks to physicians in the United States and agreed to pay a US$3 billion (£1.9bn) settlement. It was the largest health-care fraud case to date in the US and the largest settlement in the pharmaceutical industry.[10]

[Bearbeiten] Income statement

• 2025: £ 32,667 Billions (+4 %)
• 2024: £ 31,376 Billions (+3 %)
• 2023: £ 30,328 Billions (+3 %)
• 2022: £ 29,324 Billions (+19 %)
• 2021: £ 24,696 Billions (-28 %)
• 2020: £ 34,099 Billions (+1 %)
• 2019: £ 33,754 Billions

[Bearbeiten] Assets - Aktiva/Vermögenswerte

• 2025 15,96 1,22
• 2024 13,09 1,02
• 2023 12,8 1,27
• 2022 10,1 0,47
• 2021 21,34 1,03
• 2020 20,81 1,13
• 2019 18,36